 An economic evaluation of vector control in the age of a dengue vaccineChristopher Fitzpatrick, Alexander Haines, Mathieu Bangert, Andrew Farlow, Janet Hemingway and Raman Velayudhan PLOS Neglected Tropical Diseases, 2017, vol. 11, issue 8, 1-27 Abstract: Introduction: Dengue is a rapidly emerging vector-borne Neglected Tropical Disease, with a 30-fold increase in the number of cases reported since 1960. The economic cost of the illness is measured in the billions of dollars annually. Environmental change and unplanned urbanization are conspiring to raise the health and economic cost even further beyond the reach of health systems and households. The health-sector response has depended in large part on control of the Aedes aegypti and Ae. albopictus (mosquito) vectors. The cost-effectiveness of the first-ever dengue vaccine remains to be evaluated in the field. In this paper, we examine how it might affect the cost-effectiveness of sustained vector control. Methods: We employ a dynamic Markov model of the effects of vector control on dengue in both vectors and humans over a 15-year period, in six countries: Brazil, Columbia, Malaysia, Mexico, the Philippines, and Thailand. We evaluate the cost (direct medical costs and control programme costs) and cost-effectiveness of sustained vector control, outbreak response and/or medical case management, in the presence of a (hypothetical) highly targeted and low cost immunization strategy using a (non-hypothetical) medium-efficacy vaccine. Results: Sustained vector control using existing technologies would cost little more than outbreak response, given the associated costs of medical case management. If sustained use of existing or upcoming technologies (of similar price) reduce vector populations by 70–90%, the cost per disability-adjusted life year averted is 2013 US$ 679–1331 (best estimates) relative to no intervention. Sustained vector control could be highly cost-effective even with less effective technologies (50–70% reduction in vector populations) and in the presence of a highly targeted and low cost immunization strategy using a medium-efficacy vaccine. Discussion: Economic evaluation of the first-ever dengue vaccine is ongoing. However, even under very optimistic assumptions about a highly targeted and low cost immunization strategy, our results suggest that sustained vector control will continue to play an important role in mitigating the impact of environmental change and urbanization on human health. If additional benefits for the control of other Aedes borne diseases, such as Chikungunya, yellow fever and Zika fever are taken into account, the investment case is even stronger. High-burden endemic countries should proceed to map populations to be covered by sustained vector control. Author summary: Transmitted by the Aedes mosquito, dengue affects more than 100 countries and is rapidly emerging as the leading vector-borne disease. There has been a 30-fold increase in the number of cases reported since 1960. The cost of the illness to the health system and to society at large is estimated at several billions of dollars annually. The health sector response has depended in large part on controlling mosquito populations during outbreaks. Recently, the first-ever dengue vaccine received regulatory approval for use in several countries. However, its roll-out and long-term impact still needs to be evaluated in the field. In this paper, we examine how the introduction of this vaccine might alter the investment case for sustained effort to control mosquitoes. To our knowledge, this is the first economic evaluation of mosquito control in the era of the dengue vaccine. We model the cost and effects of mosquito control in Brazil, Columbia, Malaysia, Mexico, the Philippines, and Thailand. We evaluate the cost-effectiveness of mosquito control in the presence of a vaccine that does not offer full protection to all individuals. Our results suggest that sustained mosquito control will continue to be cost-effective, even if roll-out of the current vaccine is highly targeted and low-cost. These results support current global policies and strategies for the prevention and control of dengue. Date: 2017 Downloads: (external link) Related works: Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text Persistent link: https://EconPapers.repec.org/RePEc:plo:pntd00:0005785 DOI: 10.1371/journal.pntd.0005785 Access Statistics for this article More articles in PLOS Neglected Tropical Diseases from Public Library of Science |
Is your work missing from RePEc? Here is how to contribute.
Questions or problems? Check the EconPapers FAQ or send mail to .
EconPapers is hosted by the
School of Business at Örebro University.